Cardiff Oncology Inc (CRDF)

$1.55 +0.15 (10.71%)
Market Cap 95.72M
Revenue (ttm) 590,000.00
Net Income (ttm) -45.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,771.19%
Debt to Equity Ratio 0.00
Volume 1,722,300
Avg Vol 1,038,226
Day's Range N/A - N/A
Shares Out 68.37M
Stochastic %K 31%
Beta 1.36
Analysts Sell
Price Target $8.08

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
itonlymoney7
itonlymoney7 Jun. 5 at 1:54 AM
$CRDF this all about money like everything in life, the drug is very promising !!! I hope shorts one day they have to cover or there account disappears over night because it’s going to happen very fast and soon . While the big boys try to get a bite of the apple. 
0 · Reply
BioGypsy
BioGypsy Jun. 5 at 1:44 AM
$CRDF here is the reality. Cardiff can posture and act like are prepared to go it alone and dilute to support it but in reality they don’t have the staff nor expertise to do a global Phase 3. Read between the lines people that a partnership is all but inked at this point. The data has been out since March 18th. Big pharma didn’t just get access to the data this week. Assuming that is incredibly naive. Now could the nerv issue and fda guidance hold things up? Yes. But they have phase 3 design now and so once the Neev issue is removed, if not before we will get an announcement. IMO very soon, possibly next week. Why? A big pharma partner announcement will destroy Nervs leverage because big pharma will enter the legal game on Cardiffs behalf. Congrats kings
2 · Reply
jrh34
jrh34 Jun. 5 at 12:26 AM
$CRDF Well now it's pretty clear why Erlander left. Does his absence at the company prevent him from having to testify? Feels like they knew this was coming from NMS and moved Erlander out since he was involved in the patent. Sigh, all the lawyers are going to do is suck the last pennies out of this biotech that already is cash strapped.
0 · Reply
BubbaLubsGreen
BubbaLubsGreen Jun. 4 at 11:26 PM
For all that we can justifiably lament today, I personally heard a lot in both $CRDF presentations this week that gave me hope for the patients waiting for Onvansertib and for those of us who parked millions of dollars of our hard earned money here. The CEO doesn't sound overconfident. She doesn't sound like she is trying to create the air of someone sure of what she intends to do. She just sounds like a woman who has a vision and intends to do what it takes to realize it. I plan to stand by this company no matter what the bears say. Consequences be damned.
2 · Reply
GypsyGirl2
GypsyGirl2 Jun. 4 at 10:58 PM
$CRDF The Jeffries Presentation was very good imo If anyone listened? Great questions:
0 · Reply
GypsyGirl2
GypsyGirl2 Jun. 4 at 10:41 PM
$CRDF If the glove Fits? You must Acquit! CRDF has this: I’ll keep swimming… 🏊‍♂️
0 · Reply
DD_investments
DD_investments Jun. 4 at 10:13 PM
$CRDF AscendingBio on X posted the legal filing from CRDF: https://x.com/ascendingbio/status/2062637164236537941?s=46
5 · Reply
BioGypsy
BioGypsy Jun. 4 at 9:23 PM
$CRDF I see my @Core366 fanboy is admiring me today. 😂😂😂. I feel so objectified.
2 · Reply
JN75
JN75 Jun. 4 at 9:06 PM
$CRDF Bought on way down, will buy on way up. Paytience will pay.
0 · Reply
CoveredBridge
CoveredBridge Jun. 4 at 8:42 PM
$CRDF Global Data post CRDF ASCO info. today. Too lengthy for me to post. Rehash but possibly more exposure
0 · Reply
Latest News on CRDF
Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 12 hours ago

Cardiff Oncology Transcript: Jefferies Global Healthcare Conference 2026

Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2

2026-06-03T16:55:09.000Z - 1 day ago

Craig-Hallum downgrades Cardiff Oncology to Hold, lowers target to $2

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

2026-06-03T16:07:35.000Z - 1 day ago

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

Cardiff Oncology Transcript: Status update

Jun 3, 2026, 8:30 AM EDT - 1 day ago

Cardiff Oncology Transcript: Status update

Cardiff Oncology Press release: Status update

Jun 3, 2026, 8:30 AM EDT - 1 day ago

Cardiff Oncology Press release: Status update

Cardiff Oncology announces results from CRDF-004 trial

2026-06-02T14:11:15.000Z - 2 days ago

Cardiff Oncology announces results from CRDF-004 trial

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Jun 2, 2026, 9:06 AM EDT - 2 days ago

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

Jun 1, 2026, 4:01 PM EDT - 3 days ago

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright

2026-06-01T10:28:20.000Z - 3 days ago

Cardiff Oncology downgraded to Neutral from Buy at H.C. Wainwright

Cardiff Oncology says NMS terminating license agreement

2026-06-01T10:26:56.000Z - 3 days ago

Cardiff Oncology says NMS terminating license agreement

Cardiff Oncology downgraded to Hold from Buy at TD Cowen

2026-06-01T10:26:21.000Z - 3 days ago

Cardiff Oncology downgraded to Hold from Buy at TD Cowen

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

May 21, 2026, 5:00 PM EDT - 14 days ago

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

2026-05-14T21:00:37.000Z - 21 days ago

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

Cardiff Oncology sees cash, equivalents funding operations into 1Q27

2026-05-14T20:59:48.000Z - 21 days ago

Cardiff Oncology sees cash, equivalents funding operations into 1Q27

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

May 14, 2026, 4:10 PM EDT - 21 days ago

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Cardiff Oncology Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 21 days ago

Cardiff Oncology Quarterly report: Q1 2026

Cardiff Oncology Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 21 days ago

Cardiff Oncology Earnings release: Q1 2026

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2026, 4:01 PM EDT - 5 weeks ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity

Cardiff Oncology Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Cardiff Oncology Proxy statement: Proxy filing

Cardiff Oncology Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Cardiff Oncology Proxy statement: Proxy filing

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Apr 21, 2026, 10:00 AM EDT - 6 weeks ago

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Cardiff Oncology to present preclinical data on onvansertib

2026-04-17T20:14:54.000Z - 6 weeks ago

Cardiff Oncology to present preclinical data on onvansertib

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Apr 17, 2026, 4:01 PM EDT - 6 weeks ago

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO

2026-04-09T20:11:39.000Z - 2 months ago

Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO

ACRS

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Apr 9, 2026, 4:01 PM EDT - 2 months ago

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

Cardiff Oncology Transcript: KOL event

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Cardiff Oncology Transcript: KOL event

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Mar 20, 2026, 7:00 AM EDT - 2 months ago

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Feb 26, 2026, 4:01 PM EST - 3 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 1:20 PM EST - 3 months ago

Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler

2026-02-25T12:21:13.000Z - 3 months ago

Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Feb 24, 2026, 4:30 PM EST - 3 months ago

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Cardiff Oncology Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 3 months ago

Cardiff Oncology Earnings release: Q4 2025

Cardiff Oncology Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 3 months ago

Cardiff Oncology Annual report: Q4 2025

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 3 months ago

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

2026-01-28T11:15:48.000Z - 4 months ago

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

Cardiff Oncology Transcript: Study result

Jan 27, 2026, 8:30 AM EST - 4 months ago

Cardiff Oncology Transcript: Study result

Cardiff Oncology Press release: Study result

Jan 27, 2026, 8:30 AM EST - 4 months ago

Cardiff Oncology Press release: Study result

Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down

2026-01-27T12:16:42.000Z - 4 months ago

Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down

Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib

2026-01-27T12:10:44.000Z - 4 months ago

Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:05 AM EST - 4 months ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

Jan 27, 2026, 7:00 AM EST - 4 months ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Cardiff Oncology Slides: Company presentation

Jan 7, 2026, 7:00 AM EST - 5 months ago

Cardiff Oncology Slides: Company presentation

Cardiff Oncology initiated with an Outperform at Noble Capital

2026-01-05T14:01:22.000Z - 5 months ago

Cardiff Oncology initiated with an Outperform at Noble Capital

Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference

Dec 11, 2025, 4:00 PM EST - 6 months ago

Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 4:05 PM EST - 6 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Dec 8, 2025, 7:00 AM EST - 6 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:30 AM EST - 6 months ago

Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 6 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 7 months ago

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:30 AM EST - 7 months ago

Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Cardiff Oncology raises FY25 revenue view to $76M-$78M from $72M-$76M

2025-11-06T23:05:40.000Z - 7 months ago

Cardiff Oncology raises FY25 revenue view to $76M-$78M from $72M-$76M

Cardiff Oncology reports Q3 EPS (17c), consensus (21c)

2025-11-06T23:00:22.000Z - 7 months ago

Cardiff Oncology reports Q3 EPS (17c), consensus (21c)

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 7 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Cardiff Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Cardiff Oncology Earnings release: Q3 2025

Cardiff Oncology Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Cardiff Oncology Quarterly report: Q3 2025

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Nov 4, 2025, 4:01 PM EST - 7 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Oct 9, 2025, 2:00 PM EDT - 8 months ago

Cardiff Oncology Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Cardiff Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:30 AM EDT - 9 months ago

Cardiff Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Cardiff Oncology Transcript: Study Update

Jul 29, 2025, 4:30 PM EDT - 11 months ago

Cardiff Oncology Transcript: Study Update

Cardiff Oncology Press release: Study Update

Jul 29, 2025, 4:30 PM EDT - 11 months ago

Cardiff Oncology Press release: Study Update

Cardiff Oncology Slides: Study Update

Jul 29, 2025, 4:30 PM EDT - 11 months ago

Cardiff Oncology Slides: Study Update

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 4:07 PM EDT - 11 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology Earnings release: Q2 2025

Jul 29, 2025, 7:00 AM EDT - 11 months ago

Cardiff Oncology Earnings release: Q2 2025

Cardiff Oncology Quarterly report: Q2 2025

Jul 29, 2025, 7:00 AM EDT - 11 months ago

Cardiff Oncology Quarterly report: Q2 2025

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 1 year ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Earnings release: Q1 2025

Cardiff Oncology Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q1 2025

Cardiff Oncology Registration statement: Registration Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Cardiff Oncology Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Cardiff Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Cardiff Oncology Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q4 2024

Cardiff Oncology Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q4 2024

Cardiff Oncology Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Annual report: Q4 2024

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology Registration statement: Registration Filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cardiff Oncology Registration statement: Registration Filing

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology Transcript: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Transcript: Study Result

Cardiff Oncology Press release: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Press release: Study Result

Cardiff Oncology Slides: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Slides: Study Result

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Quarterly report: Q3 2024

Cardiff Oncology Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cardiff Oncology Earnings release: Q3 2024

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q2 2024

Cardiff Oncology Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Quarterly report: Q2 2024

Cardiff Oncology Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Earnings release: Q2 2024

Cardiff Oncology Proxy statement: Proxy Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Cardiff Oncology Transcript: Jefferies 2024 Global Healthcare Conference

Cardiff Oncology Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 29, 2024, 1:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

Cardiff Oncology Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 2:30 PM EDT - 2 years ago

Cardiff Oncology Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q1 2024

Cardiff Oncology Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q1 2024

Cardiff Oncology Earnings release: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q1 2024

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Cardiff Oncology Proxy statement: Proxy Filing

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Cardiff Oncology Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 1:30 PM EST - 2 years ago

Cardiff Oncology Transcript: TD Cowen 44th Annual Health Care Conference 2024

Cardiff Oncology Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q4 2023

Cardiff Oncology Earnings release: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings release: Q4 2023

Cardiff Oncology Annual report: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Annual report: Q4 2023

Cardiff Oncology Slides: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Slides: Q4 2023

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:07 PM EST - 2 years ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:06 PM EST - 2 years ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 29, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Feb 22, 2024, 8:00 AM EST - 2 years ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Jan 17, 2024, 10:30 AM EST - 2 years ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 29, 2023, 10:00 AM EST - 2 years ago

Cardiff Oncology Transcript: Piper Sandler 35th Annual Healthcare Conference

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 4:05 PM EST - 2 years ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Cardiff Oncology Earnings Call Transcript: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q3 2023

Cardiff Oncology Quarterly report: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Quarterly report: Q3 2023

Cardiff Oncology Earnings release: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings release: Q3 2023

Cardiff Oncology Slides: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Slides: Q3 2023

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Cardiff Oncology Slides: Investor Presentation

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Cardiff Oncology Slides: Investor Presentation

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

itonlymoney7
itonlymoney7 Jun. 5 at 1:54 AM
$CRDF this all about money like everything in life, the drug is very promising !!! I hope shorts one day they have to cover or there account disappears over night because it’s going to happen very fast and soon . While the big boys try to get a bite of the apple. 
0 · Reply
BioGypsy
BioGypsy Jun. 5 at 1:44 AM
$CRDF here is the reality. Cardiff can posture and act like are prepared to go it alone and dilute to support it but in reality they don’t have the staff nor expertise to do a global Phase 3. Read between the lines people that a partnership is all but inked at this point. The data has been out since March 18th. Big pharma didn’t just get access to the data this week. Assuming that is incredibly naive. Now could the nerv issue and fda guidance hold things up? Yes. But they have phase 3 design now and so once the Neev issue is removed, if not before we will get an announcement. IMO very soon, possibly next week. Why? A big pharma partner announcement will destroy Nervs leverage because big pharma will enter the legal game on Cardiffs behalf. Congrats kings
2 · Reply
jrh34
jrh34 Jun. 5 at 12:26 AM
$CRDF Well now it's pretty clear why Erlander left. Does his absence at the company prevent him from having to testify? Feels like they knew this was coming from NMS and moved Erlander out since he was involved in the patent. Sigh, all the lawyers are going to do is suck the last pennies out of this biotech that already is cash strapped.
0 · Reply
BubbaLubsGreen
BubbaLubsGreen Jun. 4 at 11:26 PM
For all that we can justifiably lament today, I personally heard a lot in both $CRDF presentations this week that gave me hope for the patients waiting for Onvansertib and for those of us who parked millions of dollars of our hard earned money here. The CEO doesn't sound overconfident. She doesn't sound like she is trying to create the air of someone sure of what she intends to do. She just sounds like a woman who has a vision and intends to do what it takes to realize it. I plan to stand by this company no matter what the bears say. Consequences be damned.
2 · Reply
GypsyGirl2
GypsyGirl2 Jun. 4 at 10:58 PM
$CRDF The Jeffries Presentation was very good imo If anyone listened? Great questions:
0 · Reply
GypsyGirl2
GypsyGirl2 Jun. 4 at 10:41 PM
$CRDF If the glove Fits? You must Acquit! CRDF has this: I’ll keep swimming… 🏊‍♂️
0 · Reply
DD_investments
DD_investments Jun. 4 at 10:13 PM
$CRDF AscendingBio on X posted the legal filing from CRDF: https://x.com/ascendingbio/status/2062637164236537941?s=46
5 · Reply
BioGypsy
BioGypsy Jun. 4 at 9:23 PM
$CRDF I see my @Core366 fanboy is admiring me today. 😂😂😂. I feel so objectified.
2 · Reply
JN75
JN75 Jun. 4 at 9:06 PM
$CRDF Bought on way down, will buy on way up. Paytience will pay.
0 · Reply
CoveredBridge
CoveredBridge Jun. 4 at 8:42 PM
$CRDF Global Data post CRDF ASCO info. today. Too lengthy for me to post. Rehash but possibly more exposure
0 · Reply
Javiergame4
Javiergame4 Jun. 4 at 8:39 PM
$CRDF anyone losing faith in crdf or are you more Bullish than ever ?
4 · Reply
Lord_Andrew_London
Lord_Andrew_London Jun. 4 at 8:29 PM
$CRDF I know that many would think I am Crazy,buy this Company can be worth 20Usd per stare,if the embedded potential Will be unleashed.Strong buy
3 · Reply
BullRun4
BullRun4 Jun. 4 at 7:55 PM
$CRDF There is still clear indicators that strong accumulation is currently taking place so don’t let an shorty scare you from investing in Cardiff Oncology and their amazing cancer therapy Onvansertib. Keep buying and holding at this super discounted price!!! GLTA the all long term bull investors and to the new investors as well.
0 · Reply
jrh34
jrh34 Jun. 4 at 7:53 PM
$CRDF Prediction: $1.00 /share dilution on Monday, likely 100 million shares. 50% consumed by institutions. You can tell that stepwise move today is preparing for the inevitable.
1 · Reply
Teskonik
Teskonik Jun. 4 at 7:51 PM
$CRDF targeting 2 after a basewalk.
0 · Reply
Vavavoom
Vavavoom Jun. 4 at 7:45 PM
$CRDF short short short
0 · Reply
Core366
Core366 Jun. 4 at 7:29 PM
$CRDF Here we go, yet another " dumb ass" mark my words we will be way over 5 in no time" bs. How many times you been SOOO WRONG EVERY TIME about your price predictions and buyout dates...oh thats right , every dumb ass time, captain frogman2000 with erlander dork pic as your own, now this biogypTARD username. FFS, did you ask AI For that 5 dollar in no time charlatan statement? yup ya did...
2 · Reply
BioGypsy
BioGypsy Jun. 4 at 7:17 PM
$CRDF @jrh34 you can’t get the dumb out of dumbass. They always go together. Congrats Yahoo. You are dumbass on two message boards now! 😂😂
1 · Reply
jrh34
jrh34 Jun. 4 at 7:15 PM
$CRDF Shrinking cash combined with a company wrapped up in litigation never has a happy ending. Just lots of hopium.
1 · Reply
Huber65
Huber65 Jun. 4 at 7:13 PM
$CRDF don’t have to be under $1 to do it. Look at GSAT. And they did pretty well after reverse split . Wanted more institutional interest at higher price.
0 · Reply
BioGypsy
BioGypsy Jun. 4 at 7:11 PM
$CRDF for everyone RS …when it happens it’s due to the following - weak data - sub 1$ compliance threat after 4 months being sub dollar - institutional gutting due to being sub 1$ Yes some Tutes require 5$ or more to invest but we have plenty of whales in very deep. We will be way over 5$ for those concerned about that in no time. For those looking at IMUX,,, they traded at .30-.50 cents for months before getting their share price to 1.15$ when the RS happened. Has zero similarities to CRDF
1 · Reply
Cutlass
Cutlass Jun. 4 at 7:10 PM
$CRDF Overnight gap at 1.58 to fill - ✍️
0 · Reply